Market Cap | 14.94M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -9.35M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 21.00% |
Sales | 1M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -35.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -84.00% |
Recommedations | - | Quick Ratio | 0.64 | Shares Outstanding | 30.74M | 52W Low Chg | 81.00% |
Insider Own | 70.47% | ROA | -119.35% | Shares Float | 8.56M | Beta | 0.14 |
Inst Own | 9.93% | ROE | -1,629.02% | Shares Shorted/Prior | 281.55K/27.93K | Price | 0.67 |
Gross Margin | 73.52% | Profit Margin | - | Avg. Volume | 60,261 | Target Price | - |
Oper. Margin | -1,582.48% | Earnings Date | - | Volume | 53,228 | Change | 1.82% |
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Soane David | 10% Owner 10% Owner | Sep 11 | Buy | 0.51 | 117,360 | 59,854 | 284,328 | 09/12/23 |
Cherington Charles | 10% Owner 10% Owner | Sep 11 | Buy | 0.5112 | 2,053,789 | 1,049,897 | 5,813,650 | 09/11/23 |
Cherington Charles | 10% Owner 10% Owner | Jul 31 | Buy | 0.5113 | 880,195 | 450,044 | 3,759,861 | 08/25/23 |
Soane David | 10% Owner 10% Owner | Jul 31 | Buy | 0.51 | 273,838 | 139,657 | 225,648 | 08/02/23 |
FINCK BARBARA K | Director Director | Jan 04 | Buy | 1.23 | 6,756 | 8,310 | 23,033 | 02/14/23 |
Sullivan Edward Aloysius Jr. | Director Director | Jan 04 | Buy | 1.23 | 10,979 | 13,504 | 19,665 | 02/14/23 |
Soane David | 10% Owner 10% Owner | Jan 04 | Buy | 1.23 | 202,701 | 249,322 | 88,729 | 01/06/23 |
Soane David | 10% Owner 10% Owner | Nov 08 | Buy | 1.3826 | 3,000 | 4,148 | 3,268,995 | 11/09/22 |
Cherington Charles | 10% Owner 10% Owner | Sep 29 | Buy | 1.8702 | 17,900 | 33,477 | 604,930 | 09/30/22 |
Sherblom James | Director Director | Sep 12 | Buy | 2.03 | 50,000 | 101,500 | 371,163 | 09/12/22 |
Campbell Michael Gerard | EVP & CFO EVP & CFO | Sep 08 | Buy | 2.07 | 25,000 | 51,750 | 25,000 | 09/12/22 |
Hackman Jeffrey S. | See Remarks See Remarks | Sep 09 | Buy | 2.06 | 47,600 | 98,056 | 47,600 | 09/12/22 |